Pre-operative Immunotherapy Combination Strategies in Breast Cancer
Asan Medical Center
Queen Mary University of London

      International, open label, window of opportunity phase II trial that aims to evaluate the
      effects of immunotherapy based treatment combinations in women with untreated, histologically
      confirmed, operable, ER+, HER2-negative breast cancer.
    
Drug